No Data
With EPS Growth And More, Jacobson Pharma (HKG:2633) Makes An Interesting Case
Hong Kong stocks are moving | JACOBSON PHARMA (02633) rose nearly 6%, with a cumulative increase of over 60% in stock price over the past six months. Mid-term sustainable operating business profit has significantly increased.
JACOBSON PHARMA (02633) rose nearly 6%, with the stock price increasing over 60% in the past six months. As of the time of writing, it is up 5.83%, trading at 1.09 Hong Kong dollars, with a transaction volume of 14.0006 million Hong Kong dollars.
China Securities Co.,Ltd.: Policy encouragement + new technology promotion + overseas opportunities create new chances, maintaining a bullish outlook on the Innovative Drugs industry.
National policies encourage the development of Innovative Drugs, new technologies promote the rapid growth of the Industry, new opportunities arise for going overseas, and there is a continuous Bullish outlook for the Innovative Drugs Industry.
WuXi AppTec leads the surge of Hong Kong stock pharmaceutical shares, while Global Biomedical investment and financing shows signs of recovery.
① The WuXi AppTec system leads the rise of Hong Kong pharmaceutical stocks, which Bullish factors are worth paying attention to? ② Global Biomedical investment and financing has seen some recovery, how do Institutions view it?
Sinolink: The policy inflection point is clear, suggesting to start increasing allocation in the pharmaceutical sector.
In the segmented Industry, it is recommended to focus on allocating resources to Innovative Drugs and left-side Sectors (such as Medical Device, Traditional Chinese Medicine, Consumer Medical, chain pharmacies, etc.) for opportunities in reverse situations of individual stocks as the two main lines.
Zhao Yin International: The Class B medical insurance catalog will be implemented within the year, Innovative Drugs will open up domestic payment space.
Zhao Yin International is Bullish on the valuation recovery of the Medical and Pharmaceutical Industry.
Jacobson Pharma's (HKG:2633) Profits Appear To Have Quality Issues
